Literature DB >> 29067678

The immunoproteasome subunit LMP7 is required in the murine thymus for filling up a hole in the T cell repertoire.

Michael Basler1,2, Sarah Mundt2, Marcus Groettrup1,2.   

Abstract

Cells of hematopoietic origin express high levels of the immunoproteasome, a cytokine-inducible variant of the proteasome which has been implicated in regulating inflammatory responses and antigen presentation. In the thymus, medullary thymic epithelial cells (mTECs) and cortical thymic epithelial cells (cTECs) do express different proteasome subunits exerting chymotrypsin-like activities suggesting distinct functions in thymic T cell selection. Employing the lymphocytic choriomeningitis virus (LCMV) infection model, we could show that the immunoproteasome subunit LMP7 was absolutely required for the generation of LCMV GP118-125 -specific T cells although the class I mediated presentation of GP118-125 was not dependent on LMP7. Using bone marrow chimeras and adoptive transfer of LMP7-deficient CD8+ T cells into RAG1-deficient mice we show that LMP7-deficient mice lacked GP118-125 -specific T cell precursors and that LMP7 was required in radioresistant cells - most likely thymic epithelial cells - to enable their selection. Since LMP7 is strongly expressed in negatively selecting mTECs but barely in positively selecting cTECs our data suggest that LMP7 was required to avoid excessive negative selection of GP118-125 -specific T cell precursors. Taken together, this study demonstrates that the immunoproteasome is a crucial factor for filling up holes within the cytotoxic T cell repertoire.
© 2017 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  Antigen processing; Immunoproteasome; LCMV; Proteasome; Thymic selection

Mesh:

Substances:

Year:  2017        PMID: 29067678     DOI: 10.1002/eji.201747282

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  8 in total

Review 1.  Tissue-specific proteasomes in generation of MHC class I peptides and CD8+ T cells.

Authors:  Mami Matsuda-Lennikov; Izumi Ohigashi; Yousuke Takahama
Journal:  Curr Opin Immunol       Date:  2022-06-08       Impact factor: 7.268

Review 2.  Peptides for T cell selection in the thymus.

Authors:  Izumi Ohigashi; Mami Matsuda-Lennikov; Yousuke Takahama
Journal:  Peptides       Date:  2021-10-05       Impact factor: 3.867

Review 3.  On the role of the immunoproteasome in transplant rejection.

Authors:  Michael Basler; Jun Li; Marcus Groettrup
Journal:  Immunogenetics       Date:  2018-09-15       Impact factor: 2.846

4.  HSCT corrects primary immunodeficiency and immune dysregulation in patients with POMP-related autoinflammatory disease.

Authors:  Caridad Martinez; Frédéric Ebstein; Sarah K Nicholas; Marietta De Guzman; Lisa R Forbes; Ottavia M Delmonte; Marita Bosticardo; Riccardo Castagnoli; Robert Krance; Luigi D Notarangelo; Elke Krüger; Jordan S Orange; M Cecilia Poli
Journal:  Blood       Date:  2021-11-11       Impact factor: 25.476

5.  Targeted Transcriptomic Analysis of C57BL/6 and BALB/c Mice During Progressive Chronic Toxoplasma gondii Infection Reveals Changes in Host and Parasite Gene Expression Relating to Neuropathology and Resolution.

Authors:  Kristina V Bergersen; Ashli Barnes; Danielle Worth; Clement David; Emma H Wilson
Journal:  Front Cell Infect Microbiol       Date:  2021-03-18       Impact factor: 5.293

Review 6.  The Role of Proteasomes in the Thymus.

Authors:  Melina Frantzeskakis; Yousuke Takahama; Izumi Ohigashi
Journal:  Front Immunol       Date:  2021-03-19       Impact factor: 7.561

Review 7.  On the Role of the Immunoproteasome in Protein Homeostasis.

Authors:  Michael Basler; Marcus Groettrup
Journal:  Cells       Date:  2021-11-18       Impact factor: 6.600

8.  Methylation of Immune-Related Genes in Peripheral Blood Leukocytes and Breast Cancer.

Authors:  Tian Tian; JinMing Fu; DaPeng Li; YuPeng Liu; HongRu Sun; Xuan Wang; XianYu Zhang; Ding Zhang; Ting Zheng; Yashuang Zhao; Da Pang
Journal:  Front Oncol       Date:  2022-02-10       Impact factor: 6.244

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.